Study of DT-216P2 in adults with Friedreich's ataxia
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests an investigational drug called DT-216P2 in people with Friedreich's ataxia. It aims to find the right dose and see how safe and tolerable it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a confirmed genetic diagnosis of Friedreich's ataxia.
- Your disease stage is 5.5 or less on the Friedreich's Ataxia Scale (a measure of disease severity).
- Your body mass index (BMI) is between 16 and 32, and you weigh no more than 100 kg (about 220 lbs).
- You are willing to use effective birth control if applicable.
- You haven't taken any other experimental drug in the last 30 days (or longer if that drug's effects last longer). If you take the drug Omaveloxolone, you must have been on a stable dose for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a single dose of a new medicine called DT-216P2 in healthy volunteers to see how safe it is and how the body handles it. It may help researchers learn more about the drug for future use.
This study follows people with Friedreich's ataxia (FA) over time to learn more about the disease. It helps researchers understand how FA affects people of all ages and may lead to better treatments.
This trial tests an injectable medicine called CTI-1601 for Friedreich's ataxia (FRDA). It is an open-label study, meaning everyone knows they are getting the drug. The study is for people who have taken CTI-1601 before (without serious side effects) or are new to the drug.
This study tests a drug called omaveloxolone (BIIB141) for children and teens with Friedreich’s Ataxia. It looks at how well the drug works and how safe it is over a longer time.
This study tests an investigational drug given as a daily injection to see if it can improve walking and balance in people with Friedreich's ataxia.
This Phase 1 trial tests an AAV gene therapy that aims to improve heart problems caused by Friedreich’s ataxia. You may be eligible if you have genetically confirmed Friedreich’s ataxia with measurable heart weakening but still enough heart function to safely receive treatment.
Hear when a new Friedreich Ataxia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.